Rituximab treatment of the anti-synthetase syndrome—a retrospective case series
Sem M et al. – This retrospective case series indicates a short-term beneficial effect of rituximab in anti-synthetase syndrome (ASS). Prospective, controlled studies are needed to validate this finding and further assess safety issues. Methods- A retrospective case series to assess ASS pts with interstitial lung disease (ILD) treated with rituximab
- 11 ASS pts; data on clinical and laboratory parameters, lung imaging by high-resolution CT thorax and pulmonary function tests were collected, 6 mo pre-treatment, and 3 and 6 mo post-treatment
Results- All 11 ASS pts had severe and progressive ILD and most of them had previously failed on cyclophosphamide and/or other immuno-modulating agents
- Rituximab appeared to stabilize and/or improve the ILD in 7/11 ASS pts during the first 6 mo after treatment
- Rituximab treatment appeared to decrease the serum level of anti-Jo-1 Ab, but the decrease was most often modest
- One patient developed a fatal infection 3 mo after the last infusion with rituximab
- In the other ASS pts, the treatment was well tolerated
[more...]
|
|
|
